EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 37 / Numéro 11 (Novembre 2021) Med Sci (Paris), 37 11 (2021) 1014-1020 Références
Contraception
Open Access
Numéro
Med Sci (Paris)
Volume 37, Numéro 11, Novembre 2021
Contraception
Page(s) 1014 - 1020
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2021163
Publié en ligne 1 décembre 2021
  1. United Nations. World population prospects: the 2019 revision. United Nations Population Division, 2019. [Google Scholar]
  2. Bongaarts J, Sitruk-Ware R. Climate change and contraception. BMJ Sex Reprod Health 2019 ; 45 : 233–235. [CrossRef] [PubMed] [Google Scholar]
  3. Bongaarts JB, O’Neill B. Global warming policy: is population left out in the cold?. Science 2018 ; 361 : 650–652. [CrossRef] [PubMed] [Google Scholar]
  4. Townsend J, Sitruk-Ware R, RamaRao S, Sailer J. Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men. Drug Deliv Transl Res 2020; 10 : 299–303. [CrossRef] [PubMed] [Google Scholar]
  5. Nations Unies. Objectifs du millénaire pour le développement - Rapport 2008. https://unstats.un.org/unsd/mdg/Resources/Static/Products/Progress2008/MDG_Report_2008_Fr.pdf. [Google Scholar]
  6. Programme des Nations Unies pour le développement. Agenda 2030 pour le développement durable. https://www.undp.org/content/undp/fr/home/2030-agenda-for-sustainable-development.html. [Google Scholar]
  7. Chun HM, Carpenter RJ, Macalino GE, Crum-Cianflone NF. The role of sexually transmitted infections in hiv-1 progression: a comprehensive review of the literature. J Sex Transm Dis 2013 ; 2013 : 176459. [PubMed] [Google Scholar]
  8. Hynes JS, Sales JM, Sheth AN. et al. Interest in multipurpose prevention technologies to prevent HIV/STIs and unintended pregnancy among young women in the United States. Contraception 2018 ; 97 : 277–284. [CrossRef] [PubMed] [Google Scholar]
  9. Sitruk-Ware R, Nath A, Mishell DR, Jr.. Contraception technology: past, present and future. Contraception 2013 ; 87 : 319–330. [CrossRef] [PubMed] [Google Scholar]
  10. Blithe DL. Pipeline for contraceptive development. Fertil Steril 2016 ; 106 : 1295–1302. [CrossRef] [PubMed] [Google Scholar]
  11. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception 2021; 103 : 213–21. [CrossRef] [PubMed] [Google Scholar]
  12. Archer DF, Merkatz RB, Bahamondes L. et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health 2019 ; 7 : e1054–e1064. [CrossRef] [PubMed] [Google Scholar]
  13. Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD. et al. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception 2019 ; 99 : 323–328. [CrossRef] [PubMed] [Google Scholar]
  14. Jensen JT, Edelman AB, Chen BA. et al. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study. Contraception 2018 ; 97 : 422–427. [CrossRef] [PubMed] [Google Scholar]
  15. Chen MJ, Creinin MD, Turok DK, et al. Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. Contraception 2020; 102 : 168–73. [CrossRef] [PubMed] [Google Scholar]
  16. Scarabin PY, Canonico M, Plu-Bureau G, Oger E. Menopause and hormone therapy in the 21st century: why promote transdermal estradiol and progesterone? Heart 2020; 106 : 1278. [Google Scholar]
  17. Roy M, Hazra A, Merkatz R, et al. Progesterone vaginal ring study group at participating centers progesterone vaginal ring as a new contraceptive option for lactating mothers: evidence from a multicenter non-randomized comparative clinical trial in India. Contraception 2020; 102 : 159–67. [CrossRef] [PubMed] [Google Scholar]
  18. Boyd P, Fetherston SM, McCoy CF. et al. Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. Int J Pharm 2016 ; 511 : 619–629. [CrossRef] [PubMed] [Google Scholar]
  19. Smith JM, Moss JA, Srinivasan P. et al. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. PLoS One 2017 ; 12 : e0185946. [CrossRef] [PubMed] [Google Scholar]
  20. Reeves MF, Katz BH, Canela JM. et al. A randomized comparison of a novel nitinol-frame low-dose-copper intrauterine contraceptive and a copper T380S intrauterine contraceptive. Contraception 2017 ; 95 : 544–548. [CrossRef] [PubMed] [Google Scholar]
  21. OCONMED. https://www.oconmed.com/en/contraception/intrauterine-ball-iub/. [Google Scholar]
  22. Hsia JK, Creinin MD. Intrauterine contraception. Semin Reprod Med 2016 ; 34 : 175–182. [CrossRef] [PubMed] [Google Scholar]
  23. Hu LX, Hu SF, Rao M. et al. Studies of acute and subchronic systemic toxicity associated with a copper/low-density polyethylene nanocomposite intrauterine device. Int J Nanomedicine 2018 ; 13 : 4913–4926. [CrossRef] [Google Scholar]
  24. Tian K, Xie C, Xia X. Chitosan/alginate multilayer film for controlled release of IDM on Cu/LDPE composite intrauterine devices. Colloids Surf B Biointerfaces 2013 ; 1 : 109: 82–89. [CrossRef] [PubMed] [Google Scholar]
  25. Brache V, Sales Viera C, Plagianos M, et al. Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: a randomized proof-of-concept study. Contraception 2021; S0010–7824(21)00193–1. [Google Scholar]
  26. ANSM. Résumé des caractéristiques du produit. Jaydess. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0224926.htm. [Google Scholar]
  27. Johnson AR, Forster SP, White D, et al. Drug eluting implants in pharmaceutical development and clinical practice. Expert Opin Drug Deliv 2021; 11 : 1–17. [Google Scholar]
  28. MedinCell BEPO®. https://www.medincell.com/bepo/. [Google Scholar]
  29. Paredes AJ, Ramöller IK, McKenna PE, et al. Microarray patches: breaking down the barriers to contraceptive care and HIV prevention for women across the globe. Adv Drug Deliv Rev 2021; 5 : S0169–409X. [Google Scholar]
  30. Blakney AK, Krogstad EA, Jiang YH, Woodrow KA. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Int J Nanomedicine 2014 ; 9 : 2967–2978. [CrossRef] [PubMed] [Google Scholar]
  31. Derby N, Lal M, Aravantinou M. et al. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo. Nat Commun 2018 ; 9 : 3881. [CrossRef] [PubMed] [Google Scholar]
  32. Vigani B, Rossi S, Sandri G, et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes. Pharmaceutics 2020; 12 : 859. [CrossRef] [Google Scholar]
  33. Notario-Perez F, Martin-Illana A, Cazorla-Luna R, et al. Mucoadhesive vaginal discs based on cyclodextrin and surfactants for the controlled release of antiretroviral drugs to prevent the sexual transmission of HIV. Pharmaceutics 2020; 12 : 321. [CrossRef] [Google Scholar]
  34. Nel AM, Mitchnick LB, Risha P. et al. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J Womens Health (Larchmt) 2011 ; 20 : 1207–1214. [CrossRef] [PubMed] [Google Scholar]
  35. Villarruel Mendoza LA, Scilletta NA, Bellino MG, et al. Recent advances in micro-electro-mechanical devices for controlled drug release applications. Front Bioeng Biotechnol 2020; 8 : 827. [CrossRef] [PubMed] [Google Scholar]
  36. Conti M, Hsieh M, Zamah AM, Jeong SO. Novel signaling mechanisms in the ovary during oocyte maturation and ovulation. Mol Cell Endocrinol 2012 ; 356 : 65–73. [CrossRef] [PubMed] [Google Scholar]
  37. Hanna CB, Yao S, Patta MC. et al. WEE2 is an oocyte-specific meiosis inhibitor in rhesus macaque monkeys. Biol Reprod 2010 ; 82 : 1190–1197. [CrossRef] [PubMed] [Google Scholar]
  38. Liu PY, Swerdloff RS, Anawalt BD. et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 2008 ; 93 : 1774–1783. [CrossRef] [PubMed] [Google Scholar]
  39. Ilani N, Roth MY, Amory JK. et al. New combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab 2012 ; 97 : 3476–3486. [CrossRef] [PubMed] [Google Scholar]
  40. Roth MY, Shih G, Ilani N. et al. Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception 2014 ; 90 : 407–412. [CrossRef] [PubMed] [Google Scholar]
  41. Anawalt BD, Roth MY, Ceponis J. et al. Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology 2019 ; 7 : 878–887. [CrossRef] [PubMed] [Google Scholar]
  42. Yuen F, Wu S, Thirumalai A. et al. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Andrology 2019 ; 7 : 235–243. [CrossRef] [PubMed] [Google Scholar]
  43. Heinemann K, Saad F, Wiesemes M. et al. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 2005 ; 20 : 549–556. [CrossRef] [PubMed] [Google Scholar]
  44. Long JE, Lee MS, Blithe DL. Update on novel hormonal and non-hormonal male contraceptive development. J Clin Endocrinol Metab. 2021 Jan 22. [PubMed] [Google Scholar]
  45. Nieschlag E, Kumar N, Sitruk-Ware R. 7alpha-methyl-19-nortestosterone (MENT™): the Population Council’s contribution to research on male contraception and treatment of hypogonadism. Contraception 2013 ; 87 : 288–295. [CrossRef] [PubMed] [Google Scholar]
  46. Nguyen BT, Farrant MT, Anawalt BD, et al. Acceptability of oral dimethandrolone undecanoate in a 28-day placebo-controlled trial of a hormonal male contraceptive prototype. Contraception 2020; 102 : 52–7. [CrossRef] [PubMed] [Google Scholar]
  47. Abbe CR, Page ST, Thirumalai A. Male contraception. Yale J Biol Med 2020; 93 : 603–13. [PubMed] [Google Scholar]
  48. Matzuk MM, McKeown MR, Filippakopoulos P. et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012 ; 150 : 673–684. [CrossRef] [PubMed] [Google Scholar]
  49. O’Rand MG, Widgren EE, Beyler S, Richardson RT. Inhibition of human sperm motility by contraceptive anti-eppin antibodies from infertile male monkeys: effect on cyclic adenosine monophosphate. Biol Reprod 2009 ; 80 : 279–285. [CrossRef] [PubMed] [Google Scholar]
  50. Lishko PV, Mannowetz N. CatSper: a unique calcium channel of the sperm flagellum. Curr Opin Physiol 2018 ; 2 : 109–113. [CrossRef] [PubMed] [Google Scholar]
  51. Mok KW, Mruk DD, Lie PPY. et al. Adjudin, a potential male contraceptive, exerts its effects locally in the seminiferous epithelium of mammalian testes. Reproduction 2011 ; 141 : 571–580. [CrossRef] [PubMed] [Google Scholar]
  52. Aydin H, Sultana A, Li S, Thavalingam A, Lee JE. Molecular architecture of the human sperm IZUMO1 and egg JUNO fertilization complex. Nature 2016 ; 534 : 562–565. [CrossRef] [PubMed] [Google Scholar]
  53. Jean C, Haghighirad F, Zhu Y. et al. JUNO, the receptor of sperm IZUMO1, is expressed by the human oocyte and is essential for human fertilization. Hum Reprod 2019 ; 34 : 118–126. [CrossRef] [PubMed] [Google Scholar]
  54. Waller D, Bolick D, Lissner E. et al. Azoospermia in rabbits following an intravas injection of Vasalgel. Basic Clin Androl 2016 ; 26 : 6. [PubMed] [Google Scholar]
  55. Jensen JT. Nonsurgical permanent contraception for women: let’s complete the job. Contraception 2015 ; 92 : 89–90. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.